AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 14, 2022
08 February 2022 - 12:00AM
Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical
stage biotechnology company focused on the development and
commercialization of adeno-associated virus (AAV)-based gene
therapies for the treatment of rare and debilitating diseases with
an initial focus on inherited retinal diseases (IRDs), today
announced that it will report financial results for the quarter
ended December 31, 2021 before the market opens on Monday, February
14, 2022. AGTC management will host a conference call beginning at
8:00 AM Eastern Time on the same day to review the financial
results and provide a corporate update.
To access the call, dial 877-407-6184 (US) or
201-389-0877 (outside of the US). A live webcast will be available
in the Events and Presentations section of the Investor Relations
page at http://ir.agtc.com/events-and-presentations. Please log in
approximately 10 minutes prior to the scheduled start time. The
archived webcast will be available in the Events and Presentations
section of the company's website.
About AGTC
AGTC is a clinical-stage biotechnology company
developing genetic therapies for people with rare and debilitating
ophthalmic, otologic and central nervous system (CNS) diseases.
AGTC is a leader in designing and constructing all critical gene
therapy elements and bringing them together to develop customized
therapies with the potential to address unmet patient needs. AGTC’s
most advanced clinical programs leverage its best-in-class
technology platform to potentially improve vision for patients with
inherited retinal diseases. AGTC has active clinical trials in
X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3
and ACHM CNGA3). Its preclinical programs build on the company’s
industry leading AAV manufacturing technology and scientific
expertise. AGTC is advancing multiple important pipeline candidates
to address substantial unmet clinical needs in optogenetics,
otology and CNS disorders, and has entered into strategic
collaborations with companies including Otonomy, Inc., a
biopharmaceutical company dedicated to the development of
innovative therapeutics for neurotology, and Bionic Sight, LLC, an
innovator in the emerging field of optogenetics and retinal coding.
For more information, please visit https://agtc.com/.
IR Contact: David Carey Lazar FINN
PartnersT: (212) 867-1768 david.carey@finnpartners.com
Corporate Contact:Jonathan LieberChief
Financial OfficerApplied Genetic Technologies CorporationT: (617)
843-5778 jlieber@agtc.com
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Apr 2024 to May 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Applied Genetic Technologies Corporation (NASDAQ): 0 recent articles
More News Articles